3.49
+0.05(+1.45%)
Currency In USD
Address
188 East Blaine Street
Seattle, WA 98102
United States of America
Phone
855 226 6447
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
7
First IPO Date
March 07, 2014
| Name | Title | Pay | Year Born |
| Dr. Jonathan G. Drachman M.D. | Chief Executive Officer, Pres, Principal Financial Officer & Director | 651,294 | 1962 |
| Dr. Priti Patel M.D., M.S. | Chief Medical Officer | 512,728 | 1976 |
| Dr. Bill Arthur | Vice President & Head of Research | 0 | N/A |
| Mr. Umut Ulge | Vice President of Clinical Devel. | 0 | N/A |
| Dr. Carl Walkey Ph.D. | Senior Vice President of Corporation Devel. | 0 | 1985 |
| Mr. Kamran Alam | Senior Strategic Advisor | 0 | 1974 |
| Dr. David Baker | Co-founder & Member of Scientific Advisory Board | 0 | N/A |
| Dr. David Baker M.D., Ph.D. | Co-Founder | 0 | N/A |
| Mr. Sean Michael Smith | Interim Chief Financial Officer | 0 | 1986 |
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.